Recent Updates
Recently added Catalysts
ALT Positive Sentiment Score: 70/100

Altimmune to Participate at Two Upcoming Investor Conferences

Tuesday, November 26, 2024 1 min read
Key Takeaway: Altimmune, Inc. has announced its participation in two upcoming investor conferences, including the Annual Evercore HealthCONx Conference and the Piper Sandler Annual Healthcare Conference. The management team will be available for one-on-one meetings, and both sessions will be webcasted for wider access. This engagement reflects Altimmune's ongoing commitment to connect with investors and promote its development pipeline, particularly its GLP-1/glucagon dual receptor agonist, pemvidutide, targeting obesity and MASH.

Market Sentiment Analysis

POSITIVE FACTORS

  • Altimmune's management team is engaging with investors, which indicates confidence in their strategy.
  • Participation at two conferences may attract attention to their innovative therapies.
  • Webcast access potentially broadens outreach and engagement with stakeholders.

Full Press Release Details

GAITHERSBURG, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences:
Annual Evercore HealthCONx Conference (Coral Gables, FL)
Tuesday, December 3, 2024
Fireside Chat at 10:50 a.m. Eastern Time
Piper Sandler Annual Healthcare Conference (New York, NY)
Wednesday, December 4, 2024
Fireside Chat at 3:30 p.m. Eastern Time
The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Chief Financial Officer
Inizio Evoke, Biotech
Danielle.cantey@inizioevoke.com
This press release was published by a CLEAR® Verified individual.

Frequently Asked Questions

When is Altimmune presenting at the Evercore HealthCONx Conference?

Altimmune will present on December 3, 2024, at the Evercore HealthCONx Conference.

What is pemvidutide developed by Altimmune?

Pemvidutide is a GLP-1/glucagon dual receptor agonist aimed at treating obesity and MASH.

Where can I watch Altimmune's conference sessions?

You can watch the sessions via the Events section on Altimmune's website.

What conferences will Altimmune's management attend?

Altimmune’s management will attend the Evercore and Piper Sandler conferences.

What kind of therapeutics does Altimmune focus on?

Altimmune specializes in next-generation peptide-based therapeutics.

Tags: ALT Viatris Investor Conferences Healthcare Altimmune investor conferences pemvidutide biopharmaceuticals obesity treatment
Last updated: Nov 26, 2024